-
Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
16 Oct 2025 22:04 GMT
… Lymphoma Therapies
11.1
Key Competitors
11.2
JAYPIRCA (pirtobrutinib): Eli … Lymphoma Therapies
12.1
Key Competitors
12.2
AZD0486: AstraZeneca
12 … , Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member …
-
Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
16 Oct 2025 17:00 GMT
… , Jiangsu Hengrui Pharmaceutical Co., Ltd., Daiichi Sankyo Inc., Sanofi, Roche Pharma AG … and actionable intelligence on their competitors and markets of interest to …
-
Metastatic Prostate Cancer Market Research 2025-2035, Featuring Key Players Such as AstraZeneca, Merck, BMS, Daiichi Sankyo, Telix, Exelixis, Eli Lilly and Co, Zenith Epigenetics, MacroGenics - ResearchAndMarkets.com
13 Jun 2025 14:42 GMT
… ; Co., Inc.
Bristol Myers Squibb
Daiichi Sankyo
Telix Pharmaceuticals
Exelixis
Eli Lilly … Portfolio
3.2.3 Top Competitors
3.2.4 Target Customers …
-
Global Antibody Drug Conjugates Market Report 2025-2035, Featuring F. Hoffmann La Roche, Daiichi Sankyo, Seagen, Gilead Sciences, Takeda, Pfizer, Astellas, AstraZeneca, ADC Therapeutics and Immunogen - ResearchAndMarkets.com
21 May 2025 12:40 GMT
… F. Hoffmann La Roche Ltd, Daiichi Sankyo Company, Limited Seagen Inc., Gilead …
F. Hoffmann-La Roche Ltd.
Daiichi Sankyo Company, Limited
Seagen Inc.
Gilead … .3.3 Customer Groups and Competitors
9.3.4 Analyst…
-
Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment
29 Jul 2025 20:23 GMT
… increasing competition from companies like Daiichi Sankyo, Seagen, and ImmunoGen?
Neha Anand … oncology, setting it apart from competitors like Daiichi Sankyo, Seagen, and ImmunoGen, which … rising competition from companies like Daiichi Sankyo and ImmunoGen.
-
Ajinomoto CELLiST Korea: Delivering Confidence, Partnership, and Innovation in Cell Culture Media
13 Oct 2025 07:19 GMT
… pharmaceutical companies such as Daiichi Sankyo and Chugai.
At Daiichi Sankyo, the challenge was … raw materials, an advantage few competitors can match. This access, … leaders such as Chugai Pharmaceutical, Daiichi Sankyo, further testing its credibility …
-
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
17 Feb 2025 18:19 GMT
… tumour (TGCT), introducing competition to Daiichi Sankyo’s Turalio (pexidartinib).
TGCT is … approval positions it as a competitor to Daiichi Sankyo’s Turalio, which became …
-
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
08 Nov 2024 15:10 GMT
Daiichi Sankyo has signed a deal worth … $280 million on offer from Daiichi Sankyo if the new formulation of … a major growth product for Daiichi Sankyo and AZ, with sales across … across HER2-positive solid tumours.
Competitors are in the offing, however …
-
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight
09 Oct 2025 23:22 GMT
… Cancer (PROC)
11.1
Key Competitors
11.2
ELAHERE: AbbVie
11 … Oncology, Genelux Corporation, Advenchen Laboratories, Daiichi Sankyo, Sutro Biopharma, Merck, Kelun-Biotech … Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, among …
-
Daiichi Sankyo eyes newer cancer drugs to stave off rivals
11 Oct 2024 10:37 GMT
Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies …
About
© 1995-2025